Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Sylvia Kurz, MD, PhD
Neuro-Oncology
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Neuro-Oncology
Biography
Sylvia Kurz, MD, PhD, specializes in neuro-oncology and provides care for patients with brain tumors as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center.
An associate professor of neurology at Yale School of Medicine, Dr. Kurz's research focuses on developing new therapies and improving existing treatment protocols for brain tumors.
Dr. Kurz earned her medical and doctoral degrees from Ludwig-Maximilians-University in Germany. She completed her residency at University Hospitals Case Medical Center and a fellowship in neuro-oncology at Massachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital.
Titles
- Associate Professor of Neurology
- Associate Professor of Neurology, Neuro-Oncology
- Co-Director, Chênevert Family Brain Tumor Center
Education & Training
- Clinical FellowMassachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School (2017)
- Research FellowDana-Farber Cancer Institute Harvard Medical School (2016)
- ResidentUniversity Hospitals Case Medical Center, Case Western Reserve University (2014)
- PhDMax-Planck-Institute for Neurobiology and Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Molecular Medicine
- InternUniversity Hospitals Case Medical Center, Case Western Reserve University (2011)
- MDLudwig-Maximilians-University, School of Medicine
Languages Spoken
- English
- Deutsch (German)
Additional Information
Board Certifications
- United Council for Neurologic Subspecialties, Neuro-Oncology (2014, recertified: 2024)
Publications
- Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.
- Blondin N, Kurz S, Corbin Z, Baehring J, Omuro A. Phase I trial to evaluate the safety and tolerability of fb-PMT in patients with recurrent glioblastoma. Journal Of Clinical Oncology 2026, 44: 2070-2070. DOI: 10.1200/jco.2026.44.16_suppl.2070.
- Suryadevara C, Donaldson H, Khan H, Groff K, Kim C, Dogra S, Gautreaux J, Roberts L, Young M, Snuderl M, Zagzag D, William C, McFaline-Figueroa J, Pilar Guillermo Prieto Eibl M, Cordova C, Kurz S, Barbaro M, Placantonakis D. Neoadjuvant PD1 blockade with laser interstitial thermal therapy for recurrent high-grade glioma. Journal Of Clinical Neuroscience 2025, 145: 111823. PMID: 41456377, DOI: 10.1016/j.jocn.2025.111823.
- Leal A, Kondziolka D, Pacione D, Antwi S, Kurz S, Lin N, Adams S. Case Report: Unlocking opportunities in HER2-targeted antibody-drug conjugates for bulky leptomeningeal metastatic breast cancer. Frontiers In Oncology 2025, 15: 1559085. PMID: 40881856, PMCID: PMC12380859, DOI: 10.3389/fonc.2025.1559085.
- Rieger D, Becker H, Walter B, Dörner L, Kurz S, Niyazi M, Bodensohn R, Neumann M, Rieß O, Schroeder C, Ballin N, Ott A, Roggia C, Ossowski S, Fend F, Singer S, Nahnsen S, Kohlbacher O, Ernemann U, Sundberg Malek H, Schittenhelm J, Bitzer M, Malek N, Tatagiba M, Renovanz M, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort. Neuro-Oncology Advances 2025, 8: vdag031. PMID: 41873387, PMCID: PMC13006062, DOI: 10.1093/noajnl/vdag031.
- Kurz S, Renovanz M, Bitzer M, Niyazi M, Malek N, Tatagiba M, Tabatabai G. Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework. Neuro-Oncology Advances 2025, 7: vdaf127. PMID: 40980453, PMCID: PMC12445679, DOI: 10.1093/noajnl/vdaf127.
- Becker H, Vogelsberg A, Feucht D, Estler A, Tafrali D, Schittenhelm J, Milla J, Kurz S, Fend F, Tatagiba M, Schuhmann M, Hurth H. Case report: Solitary mass of the sciatic nerve confirmed as a primary extranodal manifestation of diffuse large B-cell lymphoma in a geriatric patient. Frontiers In Oncology 2024, 14: 1354073. PMID: 38585009, PMCID: PMC10995294, DOI: 10.3389/fonc.2024.1354073.
- Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.
- Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.
- Rieger D, Renovanz M, Kurz S, Bombach P, Paulsen F, Roder C, Tatagiba M, Niyazi M, Tabatabai G. Glioblastom – aktuelle Therapiekonzepte. Die Onkologie 2024, 30: 145-156. DOI: 10.1007/s00761-024-01473-7.
- Dörner L, Grosse L, Stange F, Hille H, Kurz S, Becker H, Volkmer S, Hippler M, Rieger D, Bombach P, Rieger J, Weinert L, Svensson L, Anders C, Cekin S, Paulsen F, Öner Ö, Ruhm K, Malek H, Möller Y, Tatagiba M, Wallwiener M, Eckert N, Escher P, Pfeifer N, Forschner A, Bauer A, Zips D, Bitzer M, Malek N, Gani C, Tabatabai G, Renovanz M. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE). Neuro-Oncology Practice 2024, 11: 336-346. PMID: 38737615, PMCID: PMC11085831, DOI: 10.1093/nop/npae002.
- Kurz S, Stammberger A, Rosahl S, Abrey L, Albert N, von Baumgarten L, Gempt J, Grosu A, Leidgens V, McLean A, Renovanz M, Schwarzenberger J, Sevenich L, Purkart T, Combs S, Tabatabai G, Hegi M, Nowosielski M. Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative. Neuro-Oncology 2023, 25: 2302-2304. PMID: 37738478, PMCID: PMC10708925, DOI: 10.1093/neuonc/noad157.
- Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. Neurology 2023, 101: e1741-e1746. PMID: 37527941, PMCID: PMC10624483, DOI: 10.1212/wnl.0000000000207670.
- Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk D, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker S, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek H, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances 2023, 5: vdad012. PMID: 36915613, PMCID: PMC10007909, DOI: 10.1093/noajnl/vdad012.
- Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A, Spino-Keeton M, Roberts L, Maloku E, Drexler S, Liechty B, Pisapia D, Krasnozhen-Ratush O, Rosenblum M, Shroff S, Boué D, Davidson C, Mao Q, Suchi M, North P, Hopp A, Segura A, Jarzembowski J, Parsons L, Johnson M, Mobley B, Samore W, McGuone D, Gopal P, Canoll P, Horbinski C, Fullmer J, Farooqi M, Gokden M, Wadhwani N, Richardson T, Umphlett M, Tsankova N, DeWitt J, Sen C, Placantonakis D, Pacione D, Wisoff J, Hidalgo E, Harter D, William C, Cordova C, Kurz S, Barbaro M, Orringer D, Karajannis M, Sulman E, Gardner S, Zagzag D, Tsirigos A, Allen J, Golfinos J, Snuderl M. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances 2023, 5: vdad076. PMID: 37476329, PMCID: PMC10355794, DOI: 10.1093/noajnl/vdad076.
- Sabari J, Velcheti V, Shimizu K, Strickland M, Heist R, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy S, Gainor J, Rajan A, Nieblas-Bedolla E, Burns A, Hallin J, Olson P, Christensen J, Kurz S, Brastianos P, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases. Clinical Cancer Research 2022, 28: 3318-3328. PMID: 35404402, PMCID: PMC9662862, DOI: 10.1158/1078-0432.ccr-22-0383.
- Strowd R, Dunbar E, Gan H, Kurz S, Jordan J, Mandel J, Mohile N, Nevel K, Taylor J, Ullrich N, Welch M, Wasilewski A, Mrugala M. Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice 2022, 9: 91-104. PMID: 35371525, PMCID: PMC8965064, DOI: 10.1093/nop/npac002.
- de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.
- Kurz S, Rogers L. Chapter 9 Vascular disorders epidemiology. 2022, 81-86. DOI: 10.1016/b978-0-12-822835-7.00060-3.
- Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.
- Tordjman M, Madelin G, Gupta P, Cordova C, Kurz S, Orringer D, Golfinos J, Kondziolka D, Ge Y, Wang R, Lazar M, Jain R. Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients. Journal Of Neuro-Oncology 2021, 152: 347-355. PMID: 33528739, PMCID: PMC8204932, DOI: 10.1007/s11060-021-03706-w.
- Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.
- Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, S A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.
- Cordova C, Kurz S. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Current Oncology Reports 2020, 22: 84. PMID: 32617743, DOI: 10.1007/s11912-020-00937-4.
- Liu E, Yu S, Sulman E, Kurz S. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. Journal Of Neuro-Oncology 2020, 149: 55-64. PMID: 32617722, DOI: 10.1007/s11060-020-03572-y.
- Fogh S, Boreta L, Nakamura J, Johnson D, S A, Kurz S. Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Neuro-Oncology Practice 2020, 8: 11-17. PMID: 33664965, PMCID: PMC7906263, DOI: 10.1093/nop/npaa037.
- Liu E, Sulman E, Wen P, Kurz S. Novel Therapies for Glioblastoma. Current Neurology And Neuroscience Reports 2020, 20: 19. PMID: 32445058, DOI: 10.1007/s11910-020-01042-6.
- Frenster J, Kader M, Kamen S, Sun J, Chiriboga L, Serrano J, Bready D, Golub D, Ravn-Boess N, Stephan G, S A, Kurz S, Jain R, Park C, Fenyo D, Liebscher I, Schöneberg T, Wiggin G, Newman R, Barnes M, Dickson J, MacNeil D, Huang X, Shohdy N, Snuderl M, Zagzag D, Placantonakis D. Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-Oncology Advances 2020, 2: vdaa053. PMID: 32642706, PMCID: PMC7262742, DOI: 10.1093/noajnl/vdaa053.
- Kurz S, Schiff D, Wen P. Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients. 2019, 717-728. DOI: 10.1007/978-3-030-04152-6_39.
- Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.
- Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.
- Kurz S, Wen P. Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma? Current Treatment Options In Neurology 2018, 20: 14. PMID: 29666934, DOI: 10.1007/s11940-018-0499-0.
Departments and Programs
Locations
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Sylvia Kurz, MD, PhD, specializes in neuro-oncology and provides care for patients with brain tumors as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center.
An associate professor of neurology at Yale School of Medicine, Dr. Kurz's research focuses on developing new therapies and improving existing treatment protocols for brain tumors.
Dr. Kurz earned her medical and doctoral degrees from Ludwig-Maximilians-University in Germany. She completed her residency at University Hospitals Case Medical Center and a fellowship in neuro-oncology at Massachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital.
Titles
- Associate Professor of Neurology
- Associate Professor of Neurology, Neuro-Oncology
- Co-Director, Chênevert Family Brain Tumor Center
Education & Training
- Clinical FellowMassachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School (2017)
- Research FellowDana-Farber Cancer Institute Harvard Medical School (2016)
- ResidentUniversity Hospitals Case Medical Center, Case Western Reserve University (2014)
- PhDMax-Planck-Institute for Neurobiology and Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Molecular Medicine
- InternUniversity Hospitals Case Medical Center, Case Western Reserve University (2011)
- MDLudwig-Maximilians-University, School of Medicine
Languages Spoken
- English
- Deutsch (German)
Additional Information
Board Certifications
- United Council for Neurologic Subspecialties, Neuro-Oncology (2014, recertified: 2024)
Publications
- Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.
- Blondin N, Kurz S, Corbin Z, Baehring J, Omuro A. Phase I trial to evaluate the safety and tolerability of fb-PMT in patients with recurrent glioblastoma. Journal Of Clinical Oncology 2026, 44: 2070-2070. DOI: 10.1200/jco.2026.44.16_suppl.2070.
- Suryadevara C, Donaldson H, Khan H, Groff K, Kim C, Dogra S, Gautreaux J, Roberts L, Young M, Snuderl M, Zagzag D, William C, McFaline-Figueroa J, Pilar Guillermo Prieto Eibl M, Cordova C, Kurz S, Barbaro M, Placantonakis D. Neoadjuvant PD1 blockade with laser interstitial thermal therapy for recurrent high-grade glioma. Journal Of Clinical Neuroscience 2025, 145: 111823. PMID: 41456377, DOI: 10.1016/j.jocn.2025.111823.
- Leal A, Kondziolka D, Pacione D, Antwi S, Kurz S, Lin N, Adams S. Case Report: Unlocking opportunities in HER2-targeted antibody-drug conjugates for bulky leptomeningeal metastatic breast cancer. Frontiers In Oncology 2025, 15: 1559085. PMID: 40881856, PMCID: PMC12380859, DOI: 10.3389/fonc.2025.1559085.
- Rieger D, Becker H, Walter B, Dörner L, Kurz S, Niyazi M, Bodensohn R, Neumann M, Rieß O, Schroeder C, Ballin N, Ott A, Roggia C, Ossowski S, Fend F, Singer S, Nahnsen S, Kohlbacher O, Ernemann U, Sundberg Malek H, Schittenhelm J, Bitzer M, Malek N, Tatagiba M, Renovanz M, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort. Neuro-Oncology Advances 2025, 8: vdag031. PMID: 41873387, PMCID: PMC13006062, DOI: 10.1093/noajnl/vdag031.
- Kurz S, Renovanz M, Bitzer M, Niyazi M, Malek N, Tatagiba M, Tabatabai G. Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework. Neuro-Oncology Advances 2025, 7: vdaf127. PMID: 40980453, PMCID: PMC12445679, DOI: 10.1093/noajnl/vdaf127.
- Becker H, Vogelsberg A, Feucht D, Estler A, Tafrali D, Schittenhelm J, Milla J, Kurz S, Fend F, Tatagiba M, Schuhmann M, Hurth H. Case report: Solitary mass of the sciatic nerve confirmed as a primary extranodal manifestation of diffuse large B-cell lymphoma in a geriatric patient. Frontiers In Oncology 2024, 14: 1354073. PMID: 38585009, PMCID: PMC10995294, DOI: 10.3389/fonc.2024.1354073.
- Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.
- Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.
- Rieger D, Renovanz M, Kurz S, Bombach P, Paulsen F, Roder C, Tatagiba M, Niyazi M, Tabatabai G. Glioblastom – aktuelle Therapiekonzepte. Die Onkologie 2024, 30: 145-156. DOI: 10.1007/s00761-024-01473-7.
- Dörner L, Grosse L, Stange F, Hille H, Kurz S, Becker H, Volkmer S, Hippler M, Rieger D, Bombach P, Rieger J, Weinert L, Svensson L, Anders C, Cekin S, Paulsen F, Öner Ö, Ruhm K, Malek H, Möller Y, Tatagiba M, Wallwiener M, Eckert N, Escher P, Pfeifer N, Forschner A, Bauer A, Zips D, Bitzer M, Malek N, Gani C, Tabatabai G, Renovanz M. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE). Neuro-Oncology Practice 2024, 11: 336-346. PMID: 38737615, PMCID: PMC11085831, DOI: 10.1093/nop/npae002.
- Kurz S, Stammberger A, Rosahl S, Abrey L, Albert N, von Baumgarten L, Gempt J, Grosu A, Leidgens V, McLean A, Renovanz M, Schwarzenberger J, Sevenich L, Purkart T, Combs S, Tabatabai G, Hegi M, Nowosielski M. Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative. Neuro-Oncology 2023, 25: 2302-2304. PMID: 37738478, PMCID: PMC10708925, DOI: 10.1093/neuonc/noad157.
- Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. Neurology 2023, 101: e1741-e1746. PMID: 37527941, PMCID: PMC10624483, DOI: 10.1212/wnl.0000000000207670.
- Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk D, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker S, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek H, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances 2023, 5: vdad012. PMID: 36915613, PMCID: PMC10007909, DOI: 10.1093/noajnl/vdad012.
- Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A, Spino-Keeton M, Roberts L, Maloku E, Drexler S, Liechty B, Pisapia D, Krasnozhen-Ratush O, Rosenblum M, Shroff S, Boué D, Davidson C, Mao Q, Suchi M, North P, Hopp A, Segura A, Jarzembowski J, Parsons L, Johnson M, Mobley B, Samore W, McGuone D, Gopal P, Canoll P, Horbinski C, Fullmer J, Farooqi M, Gokden M, Wadhwani N, Richardson T, Umphlett M, Tsankova N, DeWitt J, Sen C, Placantonakis D, Pacione D, Wisoff J, Hidalgo E, Harter D, William C, Cordova C, Kurz S, Barbaro M, Orringer D, Karajannis M, Sulman E, Gardner S, Zagzag D, Tsirigos A, Allen J, Golfinos J, Snuderl M. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances 2023, 5: vdad076. PMID: 37476329, PMCID: PMC10355794, DOI: 10.1093/noajnl/vdad076.
- Sabari J, Velcheti V, Shimizu K, Strickland M, Heist R, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy S, Gainor J, Rajan A, Nieblas-Bedolla E, Burns A, Hallin J, Olson P, Christensen J, Kurz S, Brastianos P, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases. Clinical Cancer Research 2022, 28: 3318-3328. PMID: 35404402, PMCID: PMC9662862, DOI: 10.1158/1078-0432.ccr-22-0383.
- Strowd R, Dunbar E, Gan H, Kurz S, Jordan J, Mandel J, Mohile N, Nevel K, Taylor J, Ullrich N, Welch M, Wasilewski A, Mrugala M. Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice 2022, 9: 91-104. PMID: 35371525, PMCID: PMC8965064, DOI: 10.1093/nop/npac002.
- de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.
- Kurz S, Rogers L. Chapter 9 Vascular disorders epidemiology. 2022, 81-86. DOI: 10.1016/b978-0-12-822835-7.00060-3.
- Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.
- Tordjman M, Madelin G, Gupta P, Cordova C, Kurz S, Orringer D, Golfinos J, Kondziolka D, Ge Y, Wang R, Lazar M, Jain R. Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients. Journal Of Neuro-Oncology 2021, 152: 347-355. PMID: 33528739, PMCID: PMC8204932, DOI: 10.1007/s11060-021-03706-w.
- Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.
- Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, S A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.
- Cordova C, Kurz S. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Current Oncology Reports 2020, 22: 84. PMID: 32617743, DOI: 10.1007/s11912-020-00937-4.
- Liu E, Yu S, Sulman E, Kurz S. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. Journal Of Neuro-Oncology 2020, 149: 55-64. PMID: 32617722, DOI: 10.1007/s11060-020-03572-y.
- Fogh S, Boreta L, Nakamura J, Johnson D, S A, Kurz S. Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Neuro-Oncology Practice 2020, 8: 11-17. PMID: 33664965, PMCID: PMC7906263, DOI: 10.1093/nop/npaa037.
- Liu E, Sulman E, Wen P, Kurz S. Novel Therapies for Glioblastoma. Current Neurology And Neuroscience Reports 2020, 20: 19. PMID: 32445058, DOI: 10.1007/s11910-020-01042-6.
- Frenster J, Kader M, Kamen S, Sun J, Chiriboga L, Serrano J, Bready D, Golub D, Ravn-Boess N, Stephan G, S A, Kurz S, Jain R, Park C, Fenyo D, Liebscher I, Schöneberg T, Wiggin G, Newman R, Barnes M, Dickson J, MacNeil D, Huang X, Shohdy N, Snuderl M, Zagzag D, Placantonakis D. Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-Oncology Advances 2020, 2: vdaa053. PMID: 32642706, PMCID: PMC7262742, DOI: 10.1093/noajnl/vdaa053.
- Kurz S, Schiff D, Wen P. Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients. 2019, 717-728. DOI: 10.1007/978-3-030-04152-6_39.
- Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, S. A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.
- Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.
- Kurz S, Wen P. Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma? Current Treatment Options In Neurology 2018, 20: 14. PMID: 29666934, DOI: 10.1007/s11940-018-0499-0.
Departments and Programs
Locations
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511